Business Context and Reporting Period
Cytosorbents Corp filed a Form 8-K on April 3, 2017, reporting events occurring on March 30 and March 31, 2017. The filing details the pricing of an underwritten public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise rather than operational performance. Key figures include:
- Shares Issued: 2,222,222 shares of common stock.
- Offering Price: $4.50 per share.
- Gross Proceeds: Approximately $10 million (before underwriting discounts, fees, and expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 333,333 additional shares.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transactional report.
Material Changes
The primary material change is the entry into a definitive underwriting agreement to raise capital. The company expects the transaction to close on or about April 5, 2017, subject to customary closing conditions. The shares were registered under an existing shelf registration statement (File No. 333-205806).
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future operations, or a discussion of risks beyond the standard closing conditions for the offering. The transaction is contingent on the satisfaction of customary closing conditions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected April 5, 2017).
- Confirm the net proceeds after deducting underwriting discounts and commissions.
- Check if the underwriters exercised the 30-day over-allotment option for an additional 333,333 shares.
- Review the use of proceeds as detailed in the related press releases (Exhibits 99.1 and 99.2).